沃華醫藥(002107.SZ)擬9000萬元轉讓沃華國際100%股權予北京同豐堂醫藥
格隆匯3月27日丨沃華醫藥(002107.SZ)公佈,進入2020年,突發新型冠狀病毒肺炎疫情,經濟形勢和行業發展的不確定性增強。為應對新形勢,優化資產結構、提高流動性,進而增強抗風險能力、提升核心競爭力,公司與北京同豐堂醫藥經營有限公司簽訂股權轉讓協議,將公司持有的沃華醫藥國際有限公司(沃華國際)100%的股權以人民幣9000萬元的價格轉讓予北京同豐堂醫藥經營有限公司。此次股權轉讓完成後,公司將不再持有沃華國際的股權。
沃華醫藥國際有限公司經營範圍:中藥研發、提供顧問服務。
公司轉讓全資子公司沃華醫藥國際有限公司100%的股權符合公司的實際經營情況,有利於公司應對新形勢,優化資產結構、提高資產流動性,進而增強抗風險能力、提升核心競爭力,不存在損害公司和全體股東,特別是中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.